Doxorubicin inhaled - Zivena

Drug Profile

Doxorubicin inhaled - Zivena

Alternative Names: Doxorubicin inhalation - BattellePharma; Resmycin

Latest Information Update: 08 Aug 2015

Price : $50

At a glance

  • Originator Zivena
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action P-glycoprotein inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Lung cancer

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 14 Nov 2003 Phase-II clinical trials in Lung cancer in USA (Inhalation)
  • 14 Mar 2003 Zivena is now developing inhaled doxorubicin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top